Premature Birth clinical trials at UC Irvine

4 research studies open to eligible people

Showing trials for

  • A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

    open to eligible people ages up to 6 months

    This randomized clinical trial will compare retinal outcomes with low-dose intravitreous bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1 retinopathy of prematurity (ROP). The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral visual fields.

    Irvine, California and other locations

  • Bevacizumab Treatment For Posterior Zone I ROP

    open to eligible people ages up to 6 months

    Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.

    Irvine, California and other locations

  • Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

    open to all eligible people

    This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.

    Irvine, California and other locations

  • Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)

    open to eligible people ages 22 months to 42 months

    An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.

    Orange, California and other locations

Last updated: